# MitoSense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mitosense

- Industry: Biotechnology
- Headquarters: Great Falls, US
- Website: www.mitosenseinc.com
- Total disclosed funding: $1.9M
- Latest round: Seed (Jan 11, 2024)
- Investors on record: 1

## About

Based in Virginia, US, and founded in 2019, MitoSense, Inc. operates as a biotechnology company that focuses on securing the development of treatments for neurodegenerative diseases. The company has exclusively licensed and patent-pending technology, known as Mitochondria Organelle Transplantation (MOT), to replenish mitochondria to fight various diseases, including neurodegenerative disorders. In January 2024, investor Caydan Capital Partners led a USD 3.5 million seed funding for MitoSense, Inc. 

The company offers Mitochondria Organelle Transplantation (MOT), a technology designed to combat diseases by restoring mitochondria in cells. Early research suggests its potential for alleviating symptoms of neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's. The company is engaged in collaborations to advance mitochondrial treatments, with a specific focus on neurodegenerative diseases.

## Funding rounds

- Seed, Jan 11, 2024, $1.9M — Caydan Capital Partners

## Investors

- Caydan Capital Partners (https://capitalatlas.ai/funds/caydan-capital-partners) — Seed